USDA: U.S. Pork Farmers Required to Report PEDv

Apr 21, 2014

By Amanda Brodhagen, Farms.com

A new federal policy will now require pork producers in the United States to report cases of the deadly pig virus known as Porcine Epidemic Diarrhea (PEDv). Until now, reporting was done on a voluntary basis.

The U.S. Department of Agriculture (USDA) issued the mandate on Friday [April 18].

Government officials hope that with more accurate data that they will be able to curb the virus from spreading to more U.S. farms. Since last spring, the pig virus has killed approximately four million piglets. PEDv poses no risk to human health or food safety.

More than 4,000 outbreaks of PEDv have been reported in 30 U.S. states. The USDA says it will require data on pig movement, vehicles and other traffic leaving affected farms.

In a statement, Agriculture Secretary Tom Vilsack says the USDA has been working with the pork industry to address the problem. He adds that through collaboration, government and industry have been able to establish testing protocols, sequenced the virus and are examining further how to virus is transmitted.

Pork processors like Tyson Foods have estimated that the virus could lower U.S. pork production by about two to four percent. Tightening pork supplies.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.